2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101223
    DIPPA hydrochloride 155512-52-0 99.7%
    DIPPA hydrochloride is an irreversible, long-lasting, selective and high affinity κ-opioid receptor antagonist. DIPPA hydrochloride can be used for the research of anxiety and antidepressant.
    DIPPA hydrochloride
  • HY-101233
    ICI 154129 83420-94-4
    ICI 154 129 is a delta-opioid receptor antagonist and can be used for seizure research.
    ICI 154129
  • HY-101260
    DORA-22 1088991-95-0
    DORA-22 is an orally active dual orexinergic receptor antagonist, and improves the sleep disruption and memory impairment. DORA-22 can be used for study of insomnia.
    DORA-22
  • HY-101273
    BAR502 1612191-86-2 99.53%
    BAR502 is a dual FXR and GPBAR1 agonist with IC50 values of 2 μM and 0.4 μM, respectively.
    BAR502
  • HY-101299
    (+)-Dihydrexidine hydrochloride 158704-02-0 98%
    (+)-Dihydrexidine hydrochloride ((+)-DAR-0100 hydrochloride) is a dopamine D1 receptor agonist with an EC50 of 72± 21 nM.
    (+)-Dihydrexidine hydrochloride
  • HY-101317
    TAN-67 dihydrobromide 1217628-73-3 99.20%
    TAN-67 (SB-205607) dihydrobromide is a potent and selective nonpeptidic δ-opioid receptor agonist with a Ki value of 0.647 nM. TAN-67 dihydrobromide has neuroprotective effect. TAN-67 dihydrobromide can be used in research of ischemic stroke.
    TAN-67 dihydrobromide
  • HY-101327
    Xamoterol 81801-12-9 98%
    Xamoterol (Corwin; ICI 118587) is an orally active and selective β1-adrenoceptor partial agonist. Xamoterol acts as agonist at low sympathetic tone, antagonist at high sympathetic tone, with context-dependent cardiovascular effects including modulated heart rate, blood pressure, and cardiac output. Xamoterol can be used for the research of heart failure, postural hypotension, and ischemic heart disease.
    Xamoterol
  • HY-101332
    EGLU 170984-72-2 99.79%
    EGLU ((2S)-α-Ethylglutamic acid; (2S)-α-EGLU) is a potent and competitive mGluR-2 receptor antagonist. EGLU interacts with (lS,3S)-ACPD-sensitive site with a Kd value of 66 μM. EGLU is an antidepressant agent.
    EGLU
  • HY-101334
    MPDC 159262-32-5
    MPDC is a potent and competitive inhibitor of the Na+-dependent high-affinity glutamate transporter in forebrain synaptosomes.
    MPDC
  • HY-101338
    RS-79948-197 186002-54-0 99.5%
    RS-79948-197 is a non-imidazoline α2-adrenoceptor antagonist. RS-79948-197 shows Kd values of 0.42 nM, 0.18 nM, 0.19 nM, 0.60 nM, 0.46 nM, and 0.77 nM for rat α2A, rat α2B, rat α2C, human α2A, human α2B, and human α2C, respectively.
    RS-79948-197
  • HY-101343
    RS 39604 167710-87-4 98.0%
    RS 39604 is a potent, selective, and orally active 5-HT4 receptor antagonist with a pKi of 9.1 in guinea pig striatal membranes. RS 39604 displays a low affinity (pKi<6.5) for 5-HT1A, 5-HT2C, 5-HT3, α1c, D1, D2, M1, M2, AT1, B1 and opioid mu receptors and moderate affinity for δ1, (pKi=6.8) and δ2 (pKi=7.8) sites.
    RS 39604
  • HY-101363
    1-BCP 34023-62-6 ≥99.0%
    1-BCP (Piperonylic acid piperidide) is a centrally active agent that modulates AMPA receptor gated currents. 1-BCP is a memory-enhancing agent.
    1-BCP
  • HY-101375
    (RS)-APICA 170847-18-4 99.99%
    (RS)-APICA is a selective group II metabotropic glutamate receptor (mGluR II) antagonist. (RS)-APICA shows potential neuroprotective effect.
    (RS)-APICA
  • HY-101428
    NS-638 150493-34-8 99.84%
    NS-638 is a small nonpeptide molecule with Ca2+-channel blocking properties. K+-stimulated intracellular Ca2+-elevation is blocked with an IC50 value of 3.4 μM.
    NS-638
  • HY-101578
    2614W94 205187-35-5 99.76%
    2614W94 is a selective, reversible and orally active monoamine oxidase-A (MAO-A) inhibitor with an IC50 of 5 nM and a Ki of 1.6 nM. 2614W94 shows no significant inhibition of MAO-B. 2614W94 has antidepressant and anxiolytic effects.
    2614W94
  • HY-101580
    Paliroden 188396-77-2
    Paliroden is an orally bioactive neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines, used for treatment of Alzheimer's Disease and Parkinson's.
    Paliroden
  • HY-101609
    Lesopitron dihydrochloride 132449-89-9 98.0%
    Lesopitron dihydrochloride is a full and selective 5-HT1A receptor agonist with IC50 of 125 nM in rat hippocampal membranes.
    Lesopitron dihydrochloride
  • HY-101626
    Sigma ligand-1 139652-01-0 99.67%
    Sigma ligand-1 is a selective sigma receptor ligand with an IC50s of 16 nM, 19 nM at the DTG site and the PPP site, respectively. Sigma ligand-1 has a Ki of 4000 nM at the dopamine D2 receptor.
    Sigma ligand-1
  • HY-101665
    Pagoclone 133737-32-3 ≥98.0%
    Pagoclone is an active (+)-enantiomer of the racemate RP 59037. Pagoclone is a partial GABA(A) receptor agonist used for the treatment of panic and anxiety disorders.
    Pagoclone
  • HY-101695
    EP1-antagonist-1 851204-35-8 98.60%
    EP1-antagonist-1 (Compound 27) is an EP1 antagonist with a pKi (FLIPR) of 9.31 and a pIC50 (binding) of 9.88. EP1-antagonist-1 can be used for the study of PGE2-mediated pain.
    EP1-antagonist-1
Cat. No. Product Name / Synonyms Application Reactivity